3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Motor Activity
1
Lymphoma
1
Leukemia
1
Insulin Resistance
1
Inflammation
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Interventions
Rituximab
5
fludarabine
4
Cyclophosphamide
4
pembrolizumab
2
Bendamustine Hydrochloride
2
68Ga-pentixafor
2
venetoclax
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
motexafin gadolinium
1
ibrutinib
1
fludarabine phosphate
1
daratumumab
1
brexucabtagene autoleucel
1
acalabrutinib
1
Vincristine
1
Valproic Acid
1
Transplantation
1
Tablets
1
Surveys and Questionnaires
1
Sugars
1
Stem Cell Transplantation
1
Simvastatin
1
Roflumilast
1
Ribavirin
1
Radiotherapy
1
Procarbazine
1
Positron-Emission Tomography
1
Pemetrexed
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Lymphoma
×
Tablets
×
Clear all
NCT06643221
2024-10-16
Allo-X
University of Arizona
Phase EARLY_PHASE1
Recruiting
100 enrolled